Figure 7.

Knockdown of YTHDC2 enhances radiotherapy effect in vivo. (A) Knockdown of YTHDC2 significantly enhanced radiotherapy effect (n = 5). One dose of irradiation was given at the day 6 when tumor volumes reached around 100 mm³. Photos were taken from tumor samples collected at the end of experiment (day 21). (B) The growth curve of tumors from CEN2-IRR cells transduced with viral vectors expressing shRNA-1, shRNA-3, or control sequence (n = 5). (C) Tumors weight measured at the end of experiment (day 21) (n = 5). (D) The YTHDC2 expression and inhibition of PI3K-AKT/S6 pathway in tumors was determined by western blot. (E) Representative images of immunohistostaining for examining the expression of YTHDC2, IGF1R, p-AKT, and p-S6 in xenograft tissues. Images were shown in 2 different magnifications (100×and 200×). (F) Quantitative analysis of YTHDC2, IGF1R, p-AKT, and p-S6 expression in the xenograft tumors. All experiments were repeated twice. *P < 0.05, **P < 0.01, ***P < 0.001, student's t-test.